Bergua Burgués, Juan Miguel | Hematología y Hemoterapia |

Resultados: 237
Tipo Título / Nombre Autor(es) Año
Impact of center characteristics and macroeconimic factors on the outcome of adult patients with acute lymphoblastic leukemia treated with peiatric-inspired protocols Barba P, Morgades M, Montesinos P, González Campos J..., Bergua Burgues J 2022
Midostaurin plus intensive chemotherapy in FLT3 mutated AML De la Fuente A, Diaz Beya M, Beneit P..., Bergua Burgues J 2022
Real life experience using front-line CPX-351 for therapy-related and AML-MRC: results from the spanish Pethema registry Bernal T, Rad G, Laiglesia A de, Benavente C..., Bergua Burgues J 2022
Pharmacokinetics and pharmacodynamics in first-mind: a phase IB, open-label, randomized study of tafasitamab+ + lenalidomide + R-Chop in patients with newly diagnosed diffuse large B-cell lymphoma Belada D, Kopeckova K, Bergua Burgues J, Stevens D..., Dreyling M 2022
Preliminary results of VEN-A-QUI Study: a phase 1-2 trial to assess the safety and efficacy of the combination of azacitidine or low- dose cytarabine with venetoclax and quizartinib in newly diagnosed Bergua Burgues JM, Rodríguez Veiga R, Cano I..., Casas Avilés I 2022
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia Martínez-Cuadrón D, Serrano J, Mariz J, Gil C, Tormo M..., Bergua J 2022
Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry Labrador J, Martínez-Cuadrón D, de la Fuente A, Rodríguez-Veiga R, Serrano J..., Bergua JM 2022
Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain Ribera JM, García O, Buendía-Ureña B, Terol MJ, Vicent A..., Bergua J 2022
Biomarker-driven phase Ib clinical trial of OPB-111077 in acute myeloid leukemia Martínez López J, Montesinos P, López Muñoz N, Ayala R, Martínez Sánchez P..., Bergua Burgues JM 2022
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trneny M..., Bergua-Burgués JM 2022